Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A

In conclusion, we describe the first patient in the literature with UC and hemophilia A who stayed in long-term remissi on under therapy with vedolizumab. From our point of view, vedolizumab can be safely administered in the setting of UC and hemophilia A. Antiplatelet drugs which inhibit primary hemostasis must be used with caution in this setting. Bleeding episodes can be treated safely and effectively with factor VIII (Kogenate®).Case Rep Gastroenterol 2017;11:774 –779
Source: Case Reports in Gastroenterology - Category: Gastroenterology Source Type: research